Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Non Operating Income (2016 - 2025)

Ptc Therapeutics has reported Non Operating Income over the past 14 years, most recently at $6.5 million for Q4 2025.

  • Quarterly results put Non Operating Income at $6.5 million for Q4 2025, down 26.4% from a year ago — trailing twelve months through Dec 2025 was $974000.0 (down 85.12% YoY), and the annual figure for FY2025 was $974000.0, down 85.12%.
  • Non Operating Income for Q4 2025 was $6.5 million at Ptc Therapeutics, roughly flat from $6.5 million in the prior quarter.
  • Over the last five years, Non Operating Income for PTCT hit a ceiling of $84.4 million in Q4 2022 and a floor of -$38.1 million in Q3 2022.
  • Median Non Operating Income over the past 5 years was -$1.9 million (2024), compared with a mean of -$2.0 million.
  • Biggest five-year swings in Non Operating Income: tumbled 1183.82% in 2022 and later surged 447.33% in 2025.
  • Ptc Therapeutics' Non Operating Income stood at -$31.4 million in 2021, then skyrocketed by 368.85% to $84.4 million in 2022, then tumbled by 77.52% to $19.0 million in 2023, then plummeted by 53.33% to $8.8 million in 2024, then dropped by 26.4% to $6.5 million in 2025.
  • The last three reported values for Non Operating Income were $6.5 million (Q4 2025), $6.5 million (Q3 2025), and -$5.7 million (Q2 2025) per Business Quant data.